5 Stocks to Watch: Week of 6/9/2025

Here's to the weekend! Here’s our latest list of stocks to watch for the coming week, including:

• Tax season has cooled down, but Intuit (INTU) is heating up
• 115 compelling reasons why BGC Group (BGC) is our Stock of the Week
• Why analysts are doubling down on Boston Scientific (BSX)
• Breaking down the forecasted 150% upside potential for BioCryst Pharmaceuticals (BCRX)
• Why Flex (FLEX) has unanimous Strong Buy ratings

P.S. Missed last week's picks? Get them here.

1- Boston Scientific (NYSE: BSX)

Boston Scientific produces a very wide variety of medical devices, from run-of-the-mill pacemakers to advanced stents and brain stimulation systems. BSX is one of the most widely-covered and respected biotech names on Wall Street — and for good reason. One of the Street’s top-rated analysts recently revisited their coverage of the sector — leading to a more optimistic coverage of BSX.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $102.74 — get current quote > 

Max 1-year forecast: $130.00 

Why we’re watching:

• BSX is a rare case in that it enjoys analyst coverage that is both widespread and unanimously positive — it is currently tracked by 16 analysts and has 12 Strong Buy ratings and 4 Buy ratings. See the ratings
• Moreover, the average price target for Boston Scientific shares, at $117.81, implies an 11.93% upside.  
• Citigroup researcher Joanne Wuensch (a top 5% rated analyst) recently doubled down on a prior Strong Buy rating, and increased her price target from $119 to $125.
• Wuensch's model and price target update on Boston Scientific was delivered in a post-quarterly review of names in their Healthcare (Medical Technology) sector coverage area.
• The analyst told readers that things are looking good for the sector as a whole, with fundamentals including volumes, pricing, and Capex holding.
• A few days prior to Wuensch’s revised coverage, Morgan Stanley’s Patrick Wood (a top 15% rated analyst) also reiterated a Strong Buy rating with a $125 price target.
• BSX has a Zen Rating of B, and currently ranks in the top 7% of the more than 4,600 stocks that our rating system tracks.  
• Boston Scientific shows remarkable performance in three categories — it ranks in the top 7% of stocks in terms of Sentiment, the top 11% when it comes to its Artificial Intelligence Component Grade rating, and the top 13% by Growth. (See all 7 Zen Component Grades here >)

A note from our sponsors...
Trump's Tariffs Are Reshaping Markets  

With the help from his system, Wall Street Legend reveals which companies could thrive and which could collapse under new economic policies.   

Grade any 3 stocks FREE to see if your portfolio is at risk.

2- BGC Group (NASDAQ: BGC)

Here’s our Stock of the Week, courtesy of our Zen Investor Editor-in-Chief. BGC Group clears trades across the bond, forex, and equities markets. There’s a high chance that both macro factors and the regulatory shifts will benefit the stock going forward — and once you see how high it ranks in terms of several Component Grade ratings, it’ll soon become apparent why Steve added BGC to his Zen Investor portfolio.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $9.58 — get current quote > 

Max 1-year forecast: $15.00 

Why we’re watching:

• BGC is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained why it earned a spot in his exclusive Zen Investor portfolio in a Monday article.
• While Fed rate cuts have been delayed, most experts predict that 4 cuts will occur next year. Moreover, the Trump administration is committed to cutting the red tape that constrains the financial industry — and both of these factors are tailwinds for BGC Group.
• The stock has gone under Wall Street’s radar thus far — only 2 analysts cover it, but both issue Strong Buy ratings, with an average price target of $14.50 — which implies a 56.08% upside. See the ratings
• With the stock’s impressive beat and raise earnings reports, Steve would not be surprised if BGC shares rocketed to levels near the $20 mark.
• At present, the stock has a Zen Rating of A, and ranks in the top 4% of the equities we track.
• For a better idea as to why our system rates it so highly, we have to take a look at its Component Grade ratings. BGC ranks in the top 12% in terms of Growth and Financials.
• However, the stock also ranks quite highly in terms of Artificial Intelligence and Value — in the top 14% and 16%, respectively. (See all 7 Zen Component Grades here >)

3- BioCryst Pharmaceuticals (NASDAQ: BCRX)

BioCryst Pharmaceuticals has been in business since 1986, and its primary claim to fame is the first and only once-daily treatment for a rare genetic condition. Wall Street seems to be confident in the company’s pipeline — analysts are quite bullish on BCRX, and our system ranks it quite highly in several categories.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $11.03 — get current quote > 

Max 1-year forecast: $30.00 

Why we’re watching:

• At present, 8 analysts issue ratings for BCRX shares. Of the 8, 2 rate them a Strong Buy, 5 rate them a Buy, and 1 analyst rates them a Hold. See the ratings
• The average 12-month price forecast for BCRX currently sits at $16.75, and implies a 51.72% upside from current prices.
• JP Morgan’s Jessica Fye (a top 6% rated analyst) recently doubled down on a Strong Buy rating and increased her price target from $10 to $13.
• In a similar vein, Serge Belanger of Needham (a top 5% rated analyst) reiterated a Buy rating and increased his price forecast from $15 to $17.
• Lastly (or rather, concurrently, as all of these updates came on the same day), Andrew Fein, a HC Wainwright & Co. researcher (and a top 7% rated analyst) reaffirmed a Buy rating with a Street-high price target of $30.
• For a better idea as to why analysts are so bullish, we have to take a closer look at the data that’s available to us.
• The biotech stock has a Zen Rating of A, and currently ranks in the top 4% of stocks based on an analysis of 115 proprietary factors.
• So, what are BCRX’s specific strengths? The stock ranks in the top 1% of the stocks we track in terms of Growth, but it also ranks in the top 19% in terms of Value and Artificial Intelligence. (See all 7 Zen Component Grades here >)

4- Flex (NASDAQ: FLEX)

Flex is a company that wears many hats. It helps design, build, and deliver products and entire supply chains across a wide variety of industries, including automotive, healthcare, and even cloud computing. At present, the business is reorienting itself toward high-growth and high-margin areas — chiefly data centers, and it seems to be paying off.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $42.56 — get current quote > 

Max 1-year forecast: $52.00 

Why we’re watching:

• In a clear cut case of overwhelmingly positive coverage, 7 analysts issue ratings for FLEX — all 7 rate the stock a Strong Buy. See the ratings
• Following the company’s Q4 and FY 2025 earnings call, two top-rated analysts doubled down on their bullish coverage.
• Justin Patterson of KeyBanc (a top 7% rated analyst) maintained a Strong Buy rating and increased his price target on FLEX shares from $35 to $44.
• According to Patterson, the stock was up post-print because the quarter beat consensus and management's FY 2026 guidance was higher on EPS, although lower on revenue. 
• Overall, the analyst argued that Q4 "generally surpassed lowered expectations, even though datacenter/AI headlines and narratives have changed recently."
• Barclays researcher George Wang (a top 11% rated analyst) also reiterated a Strong Buy rating, and increased his price forecast from $49 to $50.
• "The company delivered a solid quarter, and its positive mix shift is bearing fruit," Wang told investors.
• Flex ranks in the top 4% of equities on the whole, giving it an overall Zen Rating of A.
• For a better idea as to why FLEX ranks so highly, we have to take a closer look at its Component Grade ratings. When it comes to Safety, the stock ranks in the top 17%. In terms of Sentiment, it ranks in the top 12%. However, the Artificial Intelligence rating steals the show — in this regard, FLEX ranks in the top 10% of the more than 4,600 equities that we track. (See all 7 Zen Component Grades here >)

_______________________________________________________

A MESSAGE FROM OUR PARTNERS

2025 Dividend Kings List | The Best-Of-The-Best Dividend Stocks

Thousands of publicly traded companies have a dividend — that means they pay you just for owning their stock.

However, only some are able to increase their dividend payments year-after-year.

Sure Dividend researches the best dividend growth stocks for investors looking to build rising passive income over time.

And the best-of-the-best are the elite Dividend Kings.

• A stock must have 50+ consecutive years of dividend increases to be included on Sure Dividend’s Dividend King list.

Only 55 stocks qualify for the exclusive Dividend Kings list.

These are businesses that have increased their dividend every year since the 1970s, despite recessions, wars, pandemics, and changing technology.

Instantly get your complimentary Dividend Kings spreadsheet by clicking the button below:

Get My Complimentary Dividend Kings List Now

_______________________________________________________

5- Flex (NASDAQ: FLEX)

Flex is a company that wears many hats. It helps design, build, and deliver products and entire supply chains across a wide variety of industries, including automotive, healthcare, and even cloud computing. At present, the business is reorienting itself toward high-growth and high-margin areas — chiefly data centers, and it seems to be paying off.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $42.56 — get current quote > 

Max 1-year forecast: $52.00 

Why we’re watching:

• In a clear cut case of overwhelmingly positive coverage, 7 analysts issue ratings for FLEX — all 7 rate the stock a Strong Buy. See the ratings
• Following the company’s Q4 and FY 2025 earnings call, two top-rated analysts doubled down on their bullish coverage.
• Justin Patterson of KeyBanc (a top 7% rated analyst) maintained a Strong Buy rating and increased his price target on FLEX shares from $35 to $44.
• According to Patterson, the stock was up post-print because the quarter beat consensus and management's FY 2026 guidance was higher on EPS, although lower on revenue. 
• Overall, the analyst argued that Q4 "generally surpassed lowered expectations, even though datacenter/AI headlines and narratives have changed recently."
• Barclays researcher George Wang (a top 11% rated analyst) also reiterated a Strong Buy rating, and increased his price forecast from $49 to $50.
• "The company delivered a solid quarter, and its positive mix shift is bearing fruit," Wang told investors.
• Flex ranks in the top 4% of equities on the whole, giving it an overall Zen Rating of A.
• For a better idea as to why FLEX ranks so highly, we have to take a closer look at its Component Grade ratings. When it comes to Safety, the stock ranks in the top 17%. In terms of Sentiment, it ranks in the top 12%. However, the Artificial Intelligence rating steals the show — in this regard, FLEX ranks in the top 10% of the more than 4,600 equities that we track. (See all 7 Zen Component Grades here >)

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.